By 2020, demonstrate that the transmission of leprosy and malaria can be interrupted, and the new interventions pioneered by the Novartis Foundation and partners can be integrated into national programs.
Intensify the fight against leprosy by demonstrating the feasibility of an innovative approach toward zero transmission of leprosy in several sites across Asia, Africa and Latin America; and by continuing to provide free multidrug therapy (MDT) to all leprosy patients through WHO by 2020.
Launch Novartis Access in 30 countries and reach 20 million patients by the end of 2020.
By 2025, develop and validate at least one innovative healthcare delivery model that addresses the double burden of disease in underserved populations and contributes to the WHO goal of 25% reduction in non-communicable diseases (NCDs) mortality by 2025.
Assess safety and efficacy of anti-malarial development compounds KAE609 and KAF156 as treatment and prevention of malaria, considering existing and new combination partners.